The inhibition of ENPP1 differs from the pharmacologic activation of STING in a few crucial ways, even though they all elicit anti-tumor immunity through the cGAS-STING-TBK1-IRF3 signaling pathway. This evidence concerns the gene IRF3 and neoplasm.